2023-01-25 08:30:00

STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR

Logo Benzinga
Benzinga
By Pr Newswire
  • Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor models
  • STC-15 Phase 1 study in solid tumors aims to identify doses and regimen for potential clinical studies in AML and solid tumors

CAMBRIDGE, England, Jan. 25, 2023 /PRNewswire/ --STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, presented new data on its lead candidate, the METTL3 inhibitor STC-15. The new data in AML preclinical models was presented at the American Association for Cancer Research (AACR) Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome, hosted in Austin, Texas on the 23-25 January.

The presentation entitled 'STC-15, a novel METTL3 inhibitor, and its combination with venetoclax confer anti-tumour activity in AML models' detailed the study of the pharmacological inhibition of METTL3 as monotherapy or in combination with venetoclax (FDA approved for AML treatment) in models of acute myeloid leukemia (AML) in vitroand in vivo.

Continue read on benzinga.com

Logo PR Newswire
HealthPress Release2023-01-25 08:30:00
Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 18:09:00
VITRAC Therapeutics, LLC (VITRAC) initiated a Phase 1 Study of VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
Amolyt to advance pre-clinical development of anti-PTHR1 monoclonal antibodies as potential treatments of primary hyperparathyroidism (PHPT) and humoral...

Logo EIN Presswire
SAINT LOUIS, MISSOURI, USA, January 24, 2023 / EINPresswire.com / -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:30:00
ALLO-715 is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety, Efficacy and Durability with Off-the-Shelf Convenience in Multiple Myeloma SOUTH SAN...

Logo BBC
Health2023-01-24 20:00:05
Immunotherapy: 'A&E departments need more cancer expertise' Immunotherapy: 'A&E departments need more cancer expertise'Close "That was probably the...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 12:45:00
Phase 1/2 clinical trial expected to launch in early 2023 and will evaluate safety and preliminary impact on disease activity of IMPT-314 WEST HILLS, Calif.,...

Logo EIN Presswire
HealthPress Release2023-01-24 14:04:31
Emergen Research Logo Increasing number of cancer cases, rising government initiatives and projects, new drug developments, and increasing demand for...

Logo GlobeNewswire
SciencePress Release2023-01-23 12:00:00
Primary IND for solid tumor program, T-Plex, supports simultaneous use of multiple TCRs to create customized, multiplexed TCR-T cell therapies based on...

Logo BBC
HealthBy Https://Www Facebook Com/Bbcnews2023-01-24 09:00:45
Being placed on immunotherapy to treat Stage 4 cancer was a life-saver for Imogen Llewellyn. Three years on, the 34-year-old is currently cancer-free, but...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 22:45:00
Combination of A vutometinib with Defactinib Declared as Go Forward Treatment Regimen in Low-Grade Serous Ovarian Cancer (LGSOC) Program Blinded...

Logo EIN Presswire
HealthPress Release2023-01-24 12:00:00
New innovative Leukemia Diagnostic Test LENA Q51 was designed to improve patient outcomes and help in selecting the appropriate therapeutics for Leukemia...

Logo EIN Presswire
HealthPress Release2023-01-24 15:13:22
Emergen Research Logo Favorable research funding sceanrio, increase in the demand for next-generation sequencing technique in cancer profiling VANCOUVER,...

Logo EIN Presswire
HealthPress Release2023-01-23 17:53:41
Emergen Research Logo Rising incidence of Acute Myeloid Leukemia (AML) is a key factor driving FLT3 inhibitors market revenue growth FMS Like Tyrosine kinase...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 18:12:00
The Phase 3 study conducted in the U.S. will assess the efficacy and safety of the first subcutaneous long-acting Injectable (LAI) formulation of olanzapine...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 21:01:00
Second-Line GIST Patients with Mutations in KIT Exon 11 + 17/18 Only Demonstrated Substantial Clinical Benefit from QINLOCK but Not Sunitinib Company Plans...

Logo PR Newswire
HealthPress Release2023-01-23 22:00:00
DUBLIN, Jan. 23, 2023 /PRNewswire/ -- The "Ovarian Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented...

Logo GlobeNewswire
EconomyPress Release2023-01-24 14:30:00
Burlingame, Jan. 24, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, Global Cancer Therapy Market is estimated to be valued at US$ 1 84. 8 b...

Logo EIN Presswire
HealthPress Release2023-01-24 11:53:33
Uterine Cancer Drugs Market Uterine cancer is one of the most common gynecologic malignancy among female cancer patients. BURLINGAME, CA, UNITED STATES,...